Pcsk9 side effects
Pro Research Analysisby 
Searched over 200M research papers
Side Effects of PCSK9 Inhibitors: A Comprehensive Review
Introduction to PCSK9 Inhibitors
PCSK9 inhibitors are a class of drugs designed to lower low-density lipoprotein (LDL) cholesterol levels, thereby reducing the risk of cardiovascular diseases. While their efficacy in lowering cholesterol is well-documented, understanding their side effects is crucial for long-term patient safety.
Risk of Type 2 Diabetes Mellitus (T2DM)
Several studies have indicated a potential link between PCSK9 inhibitors and an increased risk of type 2 diabetes mellitus (T2DM). Genetic analyses have shown that variants in the PCSK9 gene associated with lower LDL levels are also linked to a higher risk of T2DM, increased body mass index, and central obesity . A meta-analysis of clinical trials further supports this, showing a small but significant increase in fasting blood glucose and HbA1c levels among patients treated with PCSK9 inhibitors, although this did not translate into a higher incidence of diabetes in the short term .
Neurocognitive Side Effects
The potential for neurocognitive side effects with PCSK9 inhibitors has been a topic of concern. However, multiple meta-analyses and systematic reviews have found no significant increase in the incidence of neurocognitive adverse events among patients using these drugs 68. These findings are reassuring, but long-term studies are still needed to fully understand the neurocognitive safety profile of PCSK9 inhibitors.
Cardiovascular and Mortality Outcomes
PCSK9 inhibitors have been shown to significantly reduce major adverse cardiovascular events (MACE) but their impact on overall mortality remains unclear. Some studies suggest a potential increase in all-cause mortality with certain PCSK9 inhibitors like evolocumab, while others show a decrease in serious adverse events with alirocumab 910. These mixed results highlight the need for further research to clarify the long-term cardiovascular and mortality outcomes associated with PCSK9 inhibitors.
Other Potential Side Effects
In addition to the major concerns of diabetes and neurocognitive effects, PCSK9 inhibitors have been associated with a range of other side effects. Common adverse events reported include musculoskeletal pain, nasopharyngitis, headache, back pain, and diarrhea, all of which were generally mild to moderate in severity . Genetic studies have also suggested potential links to conditions such as peptic ulcer disease, depression, asthma, chronic kidney disease, and venous thromboembolism, although these associations require further investigation .
Conclusion
PCSK9 inhibitors are effective in lowering LDL cholesterol and reducing cardiovascular events, but their long-term safety profile requires careful consideration. While the risk of T2DM and neurocognitive side effects appears to be minimal, other potential adverse effects and the impact on overall mortality need further study. Ongoing research and long-term clinical trials will be essential to fully understand the safety and efficacy of PCSK9 inhibitors in diverse patient populations.
Sources and full results
Most relevant research papers on this topic